Pharvaris (PHVS) Change in Accured Expenses (2025 - 2026)

Pharvaris posted quarterly Change in Accured Expenses of -$5.1 million for Q1 2026, down 812.72% year-on-year from $718004.1 in Q1 2025, and down 812.72% on a QoQ basis from -$560671.2 in Q1 2025.

Pharvaris (PHVS) has 2 years of Change in Accured Expenses data on file, last reported at -$5.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 931,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -176.03 Mn
10 Pharvaris 267.74 Mn -73.74 Mn - -5.12 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -5.12 Mn
Mar 31, 2026 -5.12 Mn
Mar 31, 2025 -560,671.24
Mar 31, 2025 -560,671.24